MCID: BCL006
MIFTS: 47

B-Cell Lymphomas malady

Rare diseases, Immune diseases, Cancer diseases categories

Aliases & Classifications for B-Cell Lymphomas

About this section

Aliases & Descriptions for B-Cell Lymphomas:

Name: B-Cell Lymphomas 30 42 61
Lymphoma, B-Cell 9 42
B-Cell Lymphocytic Neoplasm 8
 
B-Cell Lymphoma 8
Lymphoma B-Cell 44


Classifications:



External Ids:

Disease Ontology8 DOID:707
SNOMED-CT56 413616009
NCIt39 C27907

Summaries for B-Cell Lymphomas

About this section
Disease Ontology:8 A non-hodgkin lymphoma that has material basis in b cells.

MalaCards based summary: B-Cell Lymphomas, also known as lymphoma, b-cell, is related to hodgkin lymphoma and malt lymphoma. An important gene associated with B-Cell Lymphomas is NFKB2 (nuclear factor of kappa light polypeptide gene enhancer in B-cells 2 (p49/p100)), and among its related pathways are TFs Regulate miRNAs related to cardiac hypertrophy and Immune response NFAT in immune response. The drugs rituximab and ibritumomab tiuxetan have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone.

Related Diseases for B-Cell Lymphomas

About this section

Diseases in the B-Cell Lymphomas family:

T-Cell Lymphoma 1a

Diseases related to B-Cell Lymphomas via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 375)
idRelated DiseaseScoreTop Affiliating Genes
1hodgkin lymphoma31.7IGH, TCL1A, BCL6
2malt lymphoma31.7BCL6, IGH
3follicular lymphoma31.6IGH, TNFRSF13C, TCL1A, BCL6
4burkitt lymphoma31.6BCL6, TCL1A, IGH
5peripheral t-cell lymphoma31.5BCL6, TCL1A
6chronic lymphocytic leukemia31.4BCL6, TCL1A, IGH
7primary effusion lymphoma31.4BCL6, TCL1A
8plasmacytoma31.2BCL6, IGH
9myeloma31.1IGH, TCL1A, BCL6, NFKB2
10central nervous system lymphoma31.0BCL6
11common variable immunodeficiency31.0TNFRSF13C
12gastric lymphoma30.9BCL6, IGH
13reticulosarcoma30.4IGH, BCL6
14diffuse large b-cell lymphoma11.7
15marginal zone b-cell lymphoma11.4
16intravascular large b-cell lymphoma11.2
17mediastinitis11.1
18primary mediastinal large b-cell lymphoma11.1
19leukemia11.0
20indolent b cell lymphoma10.9
21t-cell/histiocyte rich large b cell lymphoma10.9
22primary cutaneous marginal zone b-cell lymphoma10.9
23nodal marginal zone b-cell lymphoma10.9
24hepatitis10.8
25primary cutaneous diffuse large b-cell lymphoma, leg type10.8
26epstein-barr virus-positive diffuse large b-cell lymphoma of the elderly10.8
27mantle cell lymphoma10.7
28hepatitis c10.7
29gray zone lymphoma10.7
30thyroiditis10.7
31nodular lymphocyte predominant hodgkin lymphoma10.7
32hepatitis c virus10.6
33arthritis10.6
34alk-positive large b-cell lymphoma10.6
35endotheliitis10.6
36rheumatoid arthritis10.6
37macroglobulinemia10.6
38histiocytosis10.6
39angioimmunoblastic t-cell lymphoma10.6
40prostatitis10.6
41mediastinal gray zone lymphoma10.6
42cerebritis10.6
43composite lymphoma10.6
44diffuse large b-cell lymphoma of the central nervous system10.6
45anaplastic large cell lymphoma10.6
46splenic marginal zone lymphoma10.6
47adenocarcinoma10.6
48amyloidosis10.6
49cryoglobulinemia10.5
50pemphigus10.5

Graphical network of the top 20 diseases related to B-Cell Lymphomas:



Diseases related to b-cell lymphomas

Symptoms for B-Cell Lymphomas

About this section

Drugs & Therapeutics for B-Cell Lymphomas

About this section

FDA approved drugs:

(show all 9)
id Drug Name Active Ingredient(s)13 Pharmaceutical Company Approval Date
1
Adcetris13 38 BRENTUXIMAB VEDOTIN Seattle Genetics Approved August 2011
FDA Label: Adcetris
Malady that Drug Treats: Hodgkin lymphoma and anaplastic large cell lymphoma
Indications and Usage:13 ADCETRIS is a CD30-directed antibody-drug conjugate indicated for; treatment of patients with:; Hodgkin lymphoma after failure of autologous stem cell transplant; (ASCT) or after failure of at least two prior multi-agent chemotherapy; regimens in patients who are not ASCT candidates (1.1).; Systemic anaplastic large cell lymphoma after failure of at least one; prior multi-agent chemotherapy regimen (1.2).; Accelerated approval was granted for the above indications based on; overall response rate. An improvement in patient-reported outcomes or; survival has not been established. Continued approval for these indications; may be contingent upon verification and description of clinical benefit in; confirmatory trials.
DrugBank Targets:11 Tumor necrosis factor receptor superfamily member 8
Mechanism of Action:13 
Target: microtubule
Action: disruptor
FDA: Brentuximab vedotin is an ADC. The antibody is a chimeric IgG1 directed against CD30. The; small molecule, MMAE, is a microtubule disrupting agent. MMAE is covalently attached to the; antibody via a linker. Nonclinical data suggest that the anticancer activity of ADCETRIS is due; to the binding of the ADC to CD30-expressing cells, followed by internalization of the; ADC-CD30 complex, and the release of MMAE via proteolytic cleavage. Binding of MMAE to; tubulin disrupts the microtubule network within the cell, subsequently inducing cell cycle arrest; and apoptotic death of the cells.
2
Bexxar13 38 TOSITUMOMAB; IODINE I 131 TOSITUMOMAB Corixa Approved June 2003
FDA Label: Bexxar
Malady that Drug Treats: Non-Hodgkin's Lymphoma
Indications and Usage:13 BEXXAR (tositumomab and Iodine I 131 tositumomab) is a CD20-directed; radiotherapeutic antibody indicated for the treatment of patients with CD20-; positive, relapsed or refractory, low-grade, follicular, or transformed nonHodgkin's; lymphoma who have progressed during or after rituximab therapy,; including patients with rituximab-refractory non-Hodgkin's lymphoma. (1.1); Determination of the effectiveness of the BEXXAR therapeutic regimen is; based on overall response rates in patients whose disease is refractory to; chemotherapy and rituximab. The effects of the BEXXAR therapeutic; regimen on survival are not known. (1.1); Important Limitation of Use BEXXAR therapeutic regimen is only indicated for a single course of; treatment and is not indicated for a first-line treatment. (1.2)
DrugBank Targets:11 1. B-lymphocyte antigen CD20; 2. Low affinity immunoglobulin gamma Fc region receptor III-B; 3. Complement C1r subcomponent; 4. Complement C1q subcomponent subunit A; 5. Complement C1q subcomponent subunit B; 6. Complement C1q subcomponent subunit C; 7. Low affinity immunoglobulin gamma Fc region receptor III-A; 8. High affinity immunoglobulin gamma Fc receptor I; 9. Low affinity immunoglobulin gamma Fc region receptor II-a; 10.Low affinity immunoglobulin gamma Fc region receptor II-b; 11. Low affinity immunoglobulin gamma Fc region receptor II-c
Mechanism of Action:13 
Target: CD20
Action: cytotoxic antibody
FDA: Tositumomab binds specifically to an epitope within the extracellular domain of the; 586 CD20 molecule. The CD20 molecule is expressed on normal B lymphocytes (pre-B lymphocytes; 587 to mature B lymphocytes) and on B-cell non-Hodgkin's lymphomas. The CD20 molecule is not; 588 shed from the cell surface and is not internalized following antibody binding. The BEXXAR; 589 therapeutic regimen induces cell death by emitting ionizing radiation to CD20-expressing; 590 lymphocytes or neighboring cells. In addition to cell death mediated by the radioisotope, other; 591 possible mechanisms of action include antibody-dependent cellular cytotoxicity, complement-; 592 dependent cytotoxicity, and CD20-mediated apoptosis.
3
Intron A13 38 INTERFERON ALFA-2B Schering-Plough Approved December 1997/ Approved December 1995/ Approved March 1997
FDA Label: Intron A
Malady that Drug Treats: non-Hodgkin's lymphoma/ malignant melanoma / Hepatitis C
Indications and Usage:13 Hairy Cell Leukemia INTRON® A is indicated for the treatment of patients 18 years of; age or older with hairy cell leukemia.; Malignant Melanoma INTRON A is indicated as adjuvant to surgical treatment in; patients 18 years of age or older with malignant melanoma who are free of disease but; at high risk for systemic recurrence, within 56 days of surgery.; Follicular Lymphoma INTRON A is indicated for the initial treatment of clinically; aggressive (see Clinical Pharmacology) follicular Non-Hodgkin s Lymphoma in; conjunction with anthracycline-containing combination chemotherapy in patients 18; years of age or older. Efficacy of INTRON A therapy in patients with low-grade, lowtumor; burden follicular Non-Hodgkin s Lymphoma has not been demonstrated.; Condylomata Acuminata INTRON A is indicated for intralesional treatment of selected; patients 18 years of age or older with condylomata acuminata involving external; surfaces of the genital and perianal areas (see DOSAGE AND ADMINISTRATION).; The use of this product in adolescents has not been studied.; AIDS-Related Kaposi's Sarcoma INTRON A is indicated for the treatment of selected; patients 18 years of age or older with AIDS-Related Kaposi's Sarcoma. The likelihood; of response to INTRON A therapy is greater in patients who are without systemic symptoms, who have limited lymphadenopathy and who have a relatively intact immune; system as indicated by total CD4 count.; Chronic Hepatitis C INTRON A is indicated for the treatment of chronic hepatitis C in; patients 18 years of age or older with compensated liver disease who have a history of; blood or blood-product exposure and/or are HCV antibody positive. Studies in these; patients demonstrated that INTRON A therapy can produce clinically meaningful effects; on this disease, manifested by normalization of serum alanine aminotransferase (ALT); and reduction in liver necrosis and degeneration.; A liver biopsy should be performed to establish the diagnosis of chronic hepatitis.; Patients should be tested for the presence of antibody to HCV. Patients with other; causes of chronic hepatitis, including autoimmune hepatitis, should be excluded. Prior; to initiation of INTRON A therapy, the physician should establish that the patient has; compensated liver disease. The following patient entrance criteria for compensated liver; disease were used in the clinical studies and should be considered before INTRON A; treatment of patients with chronic hepatitis C:; No history of hepatic encephalopathy, variceal bleeding, ascites, or other; clinical signs of decompensation; Bilirubin Less than or equal to 2 mg/dL; Albumin Stable and within normal limits; Prothrombin Time Less than 3 seconds prolonged; WBC Greater than or equal to 3000/mm3; Platelets Greater than or equal to 70,000/mm3; Serum creatinine should be normal or near normal.; Prior to initiation of INTRON A therapy, CBC and platelet counts should be; evaluated in order to establish baselines for monitoring potential toxicity. These tests; should be repeated at Weeks 1 and 2 following initiation of INTRON A therapy, and; monthly thereafter. Serum ALT should be evaluated at approximately 3-month intervals; to assess response to treatment (see DOSAGE AND ADMINISTRATION).; Patients with preexisting thyroid abnormalities may be treated if thyroidstimulating; hormone (TSH) levels can be maintained in the normal range by medication.; TSH levels must be within normal limits upon initiation of INTRON A treatment and TSH; testing should be repeated at 3 and 6 months (see PRECAUTIONS, Laboratory; Tests).; INTRON A in combination with REBETOL® is indicated for the treatment of; chronic hepatitis C in patients 3 years of age and older with compensated liver disease; previously untreated with alpha interferon therapy and in patients 18 years of age and; older who have relapsed following alpha interferon therapy. See REBETOL prescribing; information for additional information. Chronic Hepatitis B INTRON A is indicated for the treatment of chronic hepatitis B in; patients 1 year of age or older with compensated liver disease. Patients who have been; serum HBsAg positive for at least 6 months and have evidence of HBV replication; (serum HBeAg positive) with elevated serum ALT are candidates for treatment. Studies; in these patients demonstrated that INTRON A therapy can produce virologic remission; of this disease (loss of serum HBeAg) and normalization of serum aminotransferases.; INTRON A therapy resulted in the loss of serum HBsAg in some responding patients.; Prior to initiation of INTRON A therapy, it is recommended that a liver biopsy be; performed to establish the presence of chronic hepatitis and the extent of liver damage.; The physician should establish that the patient has compensated liver disease. The; following patient entrance criteria for compensated liver disease were used in the; clinical studies and should be considered before INTRON A treatment of patients with; chronic hepatitis B:; No history of hepatic encephalopathy, variceal bleeding, ascites, or other; signs of clinical decompensation; Bilirubin Normal; Albumin Stable and within normal limits; Prothrombin Time Adults less than 3 seconds prolonged; Pediatrics less than or equal to 2 seconds prolonged; WBC Greater than or equal to 4000/mm3; Platelets Adults greater than or equal to 100,000/mm3; Pediatrics greater than or equal to 150,000/mm3; Patients with causes of chronic hepatitis other than chronic hepatitis B or chronic; hepatitis C should not be treated with INTRON A. CBC and platelet counts should be; evaluated prior to initiation of INTRON A therapy in order to establish baselines for; monitoring potential toxicity. These tests should be repeated at treatment Weeks 1, 2,; 4, 8, 12, and 16. Liver function tests, including serum ALT, albumin, and bilirubin,; should be evaluated at treatment Weeks 1, 2, 4, 8, 12, and 16. HBeAg, HBsAg, and; ALT should be evaluated at the end of therapy, as well as 3- and 6-months posttherapy,; since patients may become virologic responders during the 6-month period; following the end of treatment. In clinical studies in adults, 39% (15/38) of responding; patients lost HBeAg 1 to 6 months following the end of INTRON A therapy. Of; responding patients who lost HBsAg, 58% (7/12) did so 1 to 6 months post-treatment.; A transient increase in ALT greater than or equal to 2 times baseline value (flare); can occur during INTRON A therapy for chronic hepatitis B. In clinical trials in adults; and pediatrics, this flare generally occurred 8 to 12 weeks after initiation of therapy and; was more frequent in responders (adults 63%, 24/38; pediatrics 59%, 10/17) than in; nonresponders (adults 27%, 13/48; pediatrics 35%, 19/55). However, in adults and; pediatrics, elevations in bilirubin greater than or equal to 3 mg/dL (greater than or equal; to 2 times ULN) occurred infrequently (adults 2%, 2/86; pediatrics 3%, 2/72) during; therapy. When ALT flare occurs, in general, INTRON A therapy should be continued unless signs and symptoms of liver failure are observed. During ALT flare, clinical; symptomatology and liver function tests including ALT, prothrombin time, alkaline; phosphatase, albumin, and bilirubin, should be monitored at approximately 2-week; intervals (see WARNINGS).
DrugBank Targets:11 1. Interferon alpha/beta receptor 2; 2. Interferon alpha/beta receptor 1
Mechanism of Action:13 
Target: intracellular oncogene expression, natural killer and cytotoxic T-cells, microphage, cytokine production
Action: stimulation, induction (unspecified effects on oncogene expression)
FDA: -
4
Mozobil13 38 PLERIXAFOR Genzyme Approved December 2008
FDA Label: Mozobil
Malady that Drug Treats: non-Hodgkin s lymphoma and multiple myeloma
Indications and Usage:13 Mozobil, a hematopoietic stem cell mobilizer, is indicated in combination; with granulocyte-colony stimulating factor (G-CSF) to mobilize; hematopoietic stem cells (HSCs) to the peripheral blood for collection and; subsequent autologous transplantation in patients with non-Hodgkin s; lymphoma and multiple myeloma. (1)
DrugBank Targets:11 1. C-X-C chemokine receptor type 4
Mechanism of Action:13 
Target: hematopoietic stem cell/ CXCR4 chemokine receptor
Action: monilizer/ inhibitor
FDA: Plerixafor is an inhibitor of the CXCR4 chemokine receptor and blocks binding of its cognate; ligand, stromal cell-derived factor-1± (SDF-1±). SDF-1± and CXCR4 are recognized to play a; role in the trafficking and homing of human hematopoietic stem cells (HSCs) to the marrow; compartment. Once in the marrow, stem cell CXCR4 can act to help anchor these cells to the; marrow matrix, either directly via SDF-1± or through the induction of other adhesion molecules.; Treatment with plerixafor resulted in leukocytosis and elevations in circulating hematopoietic; progenitor cells in mice, dogs and humans. CD34+ cells mobilized by plerixafor were capable of; engraftment with long-term repopulating capacity up to one year in canine transplantation; models.
5
Revlimid13 38 LENALIDOMIDE Celgene Approved June 2013
FDA Label: Revlimid
Malady that Drug Treats: mantle cell lymphoma
Indications and Usage:13 REVLIMID is a thalidomide analogue indicated for the treatment of patients; with:; Multiple myeloma (MM), in combination with dexamethasone (1.1).; Transfusion-dependent anemia due to low- or intermediate-1-risk; myelodysplastic syndromes (MDS) associated with a deletion 5q; abnormality with or without additional cytogenetic abnormalities (1.2).; Mantle cell lymphoma (MCL) whose disease has relapsed or progressed; after two prior therapies, one of which included bortezomib (1.3).; Limitations of Use:; REVLIMID is not indicated and is not recommended for the treatment; of patients with chronic lymphocytic leukemia (CLL) outside of; controlled clinical trials (1.4).
DrugBank Targets:11 1. Protein cereblon; 2. Tumor necrosis factor ligand superfamily member 11; 3. Cadherin-5; 4. Prostaglandin G/H synthase 2
Mechanism of Action:13 
Target: T cells and natural killer cells/ pro-inflammatory cytokines by monocytes
Action: activator/inhibitor
FDA: Lenalidomide is an analogue of thalidomide with immunomodulatory, antiangiogenic, and antineoplastic properties. Lenalidomide inhibits; proliferation and induces apoptosis of certain hematopoietic tumor cells including multiple myeloma, mantle cell lymphoma, and del (5q); myelodysplastic syndromes in vitro. Lenalidomide causes a delay in tumor growth in some in vivo nonclinical hematopoietic tumor models; including multiple myeloma. Immunomodulatory properties of lenalidomide include activation of T cells and natural killer (NK) cells, increased; numbers of NKT cells, and inhibition of pro-inflammatory cytokines (e.g., TNF-± and IL-6) by monocytes. In multiple myeloma cells, the; combination of lenalidomide and dexamethasone synergizes the inhibition of cell proliferation and the induction of apoptosis.
6
Rituxan13 38 RITUXIMAB Biogen IDEC, Genentech Approved November 1997
FDA Label: Rituxan
Malady that Drug Treats: non-hodgkin's lymphoma
Indications and Usage:13 Rituxan® (rituximab) is a CD20-directed cytolytic antibody indicated for the; treatment of patients with:; Non-Hodgkin s Lymphoma (NHL) (1.1); Chronic Lymphocytic Leukemia (CLL) (1.2); Rheumatoid Arthritis (RA) in combination with methotrexate in adult; patients with moderately-to severely-active RA who have inadequate; response to one or more TNF antagonist therapies (1.3); Granulomatosis with Polyangiitis (GPA) (Wegener s Granulomatosis) and; Microscopic Polyangiitis (MPA) in adult patients in combination with; glucocorticoids (1.4); Limitations of Use: Rituxan is not recommended for use in patients with; severe, active infections (1.5).
DrugBank Targets:11 1. Low affinity immunoglobulin gamma Fc region receptor III-B; 2. Complement C1r subcomponent; 3. Complement C1q subcomponent subunit A; 4. Complement C1q subcomponent subunit B; 5. Complement C1q subcomponent subunit C; 6. Low affinity immunoglobulin gamma Fc region receptor III-A; 7. Complement C1s subcomponent; 8. High affinity immunoglobulin gamma Fc receptor I; 9. Low affinity immunoglobulin gamma Fc region receptor II-a; 10. Low affinity immunoglobulin gamma Fc region receptor II-b; 11. Low affinity immunoglobulin gamma Fc region receptor II-c; 12. B-lymphocyte antigen CD20
Mechanism of Action:13 
Target: CD20 antigen expressed on the surface of; pre-B and mature B-lymphocytes
Action: mediator of B-cell lysis through different possible types of cytotoxicity
FDA: Rituximab is a monoclonal antibody that targets the CD20 antigen expressed on the surface of; pre-B and mature B-lymphocytes. Upon binding to CD20, rituximab mediates B-cell lysis. Possible; mechanisms of cell lysis include complement dependent cytotoxicity (CDC) and antibody dependent; cell mediated cytotoxicity (ADCC). The antibody induced apoptosis in the DHL 4 human B cell; lymphoma cell line.; B cells are believed to play a role in the pathogenesis of rheumatoid arthritis (RA) and associated; chronic synovitis. In this setting, B cells may be acting at multiple sites in the; autoimmune/inflammatory process, including through production of rheumatoid factor (RF) and; other autoantibodies, antigen presentation, T-cell activation, and/or proinflammatory cytokine; production.
7
Treanda13 38 BENDAMUSTINE HYDROCHLORIDE Cephalon Approved October 2008
FDA Label: Treanda
Malady that Drug Treats: Chronic lymphocytic leukemia and B-cell non-Hodgkin s lymphoma
Indications and Usage:13 TREANDA is an alkylating drug indicated for treatment of patients with:; Chronic lymphocytic leukemia (CLL). Efficacy relative to first line; therapies other than chlorambucil has not been established. (1.1); Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during; or within six months of treatment with rituximab or a rituximab-containing; regimen. (1.2)
DrugBank Targets: -
Mechanism of Action:13 
Target: -
Action: -
FDA: Bendamustine is a bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring.; Mechlorethamine and its derivatives form electrophilic alkyl groups. These groups form covalent bonds with electronrich; nucleophilic moieties, resulting in interstrand DNA crosslinks. The bifunctional covalent linkage can lead to cell; death via several pathways. Bendamustine is active against both quiescent and dividing cells. The exact mechanism of; action of bendamustine remains unknown.
8
Zevalin13 38 IBRITUMOMAB TIUXETAN Biogen IDEC Approved February 2002
FDA Label: Zevalin
Malady that Drug Treats: Non-Hodgkin's lymphoma
Indications and Usage:13 Zevalin is a CD20-directed radiotherapeutic antibody administered as part of; the Zevalin therapeutic regimen indicated for the treatment of patients with:; relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's; lymphoma (NHL) (1.1).; previously untreated follicular NHL who achieve a partial or complete; response to first-line chemotherapy (1.2). ;
DrugBank Targets:11 1. B-lymphocyte antigen CD20; 2. Low affinity immunoglobulin gamma Fc region receptor III-B; 3. Complement C1r subcomponent; 4. Complement C1q subcomponent subunit A; 5. Complement C1q subcomponent subunit B; 6. Complement C1q subcomponent subunit C; 7. Low affinity immunoglobulin gamma Fc region receptor III-A; 8. Complement C1s subcomponent; 9. High affinity immunoglobulin gamma Fc receptor I; 10. Low affinity immunoglobulin gamma Fc region receptor II-a; 11. Low affinity immunoglobulin gamma Fc region receptor II-b; 12. Low affinity immunoglobulin gamma Fc region receptor II-c
Mechanism of Action:13 
Target: CD20 antigen --> Y-90
Action: beta emission causes damage
FDA: Ibritumomab tiuxetan binds specifically to the CD20 antigen (human B-lymphocyte-restricted differentiation antigen,; Bp35). The apparent affinity (KD) of ibritumomab tiuxetan for the CD20 antigen ranges between approximately 14 to; 18 nM. The CD20 antigen is expressed on pre-B and mature B lymphocytes and on > 90% of B-cell non-Hodgkin s; lymphomas (NHL). The CD20 antigen is not shed from the cell surface and does not internalize upon antibody binding.; The chelate tiuxetan, which tightly binds Y-90, is covalently linked to ibritumomab. The beta emission from Y-90; induces cellular damage by the formation of free radicals in the target and neighboring cells.; Ibritumomab tiuxetan binding was observed in vitro on lymphoid cells of the bone marrow, lymph node, thymus, red and; white pulp of the spleen, and lymphoid follicles of the tonsil, as well as lymphoid nodules of other organs such as the; large and small intestines.
9
Zydelig13 38 IDELALISIB Gilead Approved July 2014
FDA Label: Zydelig
Malady that Drug Treats: relapsed CLL, follicular B-cell NHL and small lymphocytic lymphoma
Indications and Usage:13 Zydelig is a kinase inhibitor indicated for the treatment of patients with:; Relapsed chronic lymphocytic leukemia (CLL), in combination with; rituximab, in patients for whom rituximab alone would be considered; appropriate therapy due to other co-morbidities. (1.1); Relapsed follicular B-cell non-Hodgkin lymphoma (FL) in patients; who have received at least two prior systemic therapies. (1.2); Relapsed small lymphocytic lymphoma (SLL) in patients who have; received at least two prior systemic therapies. (1.3); Accelerated approval was granted for FL and SLL based on overall; response rate. Improvement in patient survival or disease related; symptoms has not been established. Continued approval for these; indications may be contingent upon verification of clinical benefit in; confirmatory trials.
DrugBank Targets:11 1. Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta isoform (P110´)
Mechanism of Action:13 
Target: PI3K´ kinase
Action: inhibitor
FDA: Idelalisib is an inhibitor of PI3K´ kinase, which is expressed in normal and malignant Bcells.; Idelalisib induced apoptosis and inhibited proliferation in cell lines derived from; malignant B-cells and in primary tumor cells. Idelalisib inhibits several cell signaling; pathways, including B-cell receptor (BCR) signaling and the CXCR4 and CXCR5; signaling, which are involved in trafficking and homing of B-cells to the lymph nodes and; bone marrow. Treatment of lymphoma cells with idelalisib resulted in inhibition of; chemotaxis and adhesion, and reduced cell viability.

Drug clinical trials:

Search ClinicalTrials for B-Cell Lymphomas

Search NIH Clinical Center for B-Cell Lymphomas

Inferred drug relations via UMLS61/NDF-RT40:

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about B-Cell Lymphomas cell therapies at LifeMap Discovery.

Genetic Tests for B-Cell Lymphomas

About this section

Anatomical Context for B-Cell Lymphomas

About this section

MalaCards organs/tissues related to B-Cell Lymphomas:

31
B cells, T cells, Bone, Bone marrow, Lung, Skin, Breast, Thyroid, Colon, Endothelial, Spleen, Liver, Prostate, Lymph node, Small intestine, Salivary gland, Uterus, Monocytes, Testis, Thymus, Brain, Myeloid, Kidney, Tonsil, Pituitary, Neutrophil, Spinal cord, B lymphoblasts, Heart, Smooth muscle, Ovary, Testes, Nk cells, Retina, Pancreas, Cervix, Appendix

Animal Models for B-Cell Lymphomas or affiliated genes

About this section

Publications for B-Cell Lymphomas

About this section

Articles related to B-Cell Lymphomas:

(show top 50)    (show all 3139)
idTitleAuthorsYear
1
Upregulation of long noncoding RNA PEG10 associates with poor prognosis in diffuse large B cell lymphoma with facilitating tumorigenicity. (25864113)
2015
2
A 44-year old male with right-sided facial numbness. Dura-associated extranodal marginal zone B cell lymphoma (MALT lymphoma). (25521183)
2015
3
Novel Immunotherapies for B-Cell Lymphomas and Leukemias. (25237982)
2014
4
Influence of polymorphisms in ERCC5, XPA and MTR DNA repair and synthesis genes in B-cell lymphoma risk. A case-control study in Spanish population. (23818366)
2013
5
Primary mediastinal large B-cell lymphoma segregating in a family: exome sequencing identifies MLL as a candidate predisposition gene. (23457195)
2013
6
Karyotyping of diffuse large B-cell lymphomas: loss of 17p is associated with poor patient outcome. (23859481)
2013
7
Activation of the STAT3 Signaling Pathway Is Associated With Poor Survival in Diffuse Large B-Cell Lymphoma Treated With R-CHOP. (24220563)
2013
8
Infusion Rate Escalation Study of Rituximab in Patients with CD20+ B-Cell Lymphomas: A Single Institution Analysis in Japan. (23691364)
2013
9
Paradoxical Regulation of Hypoxia Inducible Factor-1I+ (HIF-1I+) by Histone Deacetylase Inhibitor in Diffuse Large B-Cell Lymphoma. (24312289)
2013
10
MicroRNAs as prognostic markers in indolent primary cutaneous B-cell lymphoma. (22936066)
2013
11
An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and I9SUVmax. (23649463)
2013
12
Pediatric Burkitt's Lymphoma and Diffuse B-Cell Lymphoma: Are Surveillance Scans Required? (24087880)
2013
13
Two Cases of Diffuse Large B-Cell Lymphomas in the Cervical Lymph Nodes in Patients with Low-Grade Gastric Marginal Zone B-Cell Lymphoma (MALT Lymphoma). (23767042)
2013
14
Lenalidomide in diffuse large B-cell lymphomas. (22792112)
2012
15
A case of monoclonal gammopathy in extranodal marginal zone B-cell lymphoma of the small intestine. (21239866)
2011
16
Treatment of patients with refractory diffuse large B-cell lymphoma or mantle cell lymphoma with alemtuzumab, alone or in combination with cytotoxic chemotherapy. (21067447)
2011
17
Development of diffuse large B-cell lymphoma in a patient with WaldenstrAPm's macroglobulinemia/lymphoplasmacytic lymphoma: clonal identity between two B-cell neoplasms. (22184531)
2011
18
A fatal case of hemoperitoneum after ultrasound-guided liver biopsy in a patient with intravascular large B-cell lymphoma. (21377915)
2011
19
FOXP1 molecular cytogenetics and protein expression analyses in primary cutaneous large B cell lymphoma, leg-type. (21154235)
2011
20
Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells. (21173233)
2011
21
Pulmonary marginal zone B-cell lymphoma of MALT type--what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) study. (20024551)
2010
22
18F-FDG PET/CT in a case of intravascular large B-cell lymphoma. (20607536)
2010
23
Epigenetic down-regulation of the tumor suppressor gene PRDM1/Blimp-1 in diffuse large B cell lymphomas: a potential role of the microRNA let-7. (20651244)
2010
24
A rare reason of foot drop caused by primary diffuse large b-cell lymphoma of the sciatic nerve: case report. (19415174)
2010
25
A novel flow cytometric antibody panel for distinguishing Burkitt lymphoma from CD10+ diffuse large B-cell lymphoma. (20395518)
2010
26
Retreatment with rituximab in 178 patients with relapsed and refractory B-cell lymphomas: a single institution case control study. (20038227)
2010
27
Most primary central nervous system diffuse large B-cell lymphomas occurring in immunocompetent individuals belong to the nongerminal center subtype: a retrospective analysis of 31 cases. (19935644)
2010
28
Caspase 3a: new prognostic marker for diffuse large B-cell lymphoma in the rituximab era. (20919853)
2010
29
Primary mediastinal large B-cell lymphoma in HIV: report of two cases. (19669223)
2009
30
Nuclear expression of YB-1 in diffuse large B-cell lymphoma: correlation with disease activity and patient outcome. (19500133)
2009
31
BCL2 expression in de novo diffuse large B-cell lymphoma partly reflects normal differences in age distribution. (19508293)
2009
32
Small-molecule XIAP antagonist restores caspase-9 mediated apoptosis in XIAP-positive diffuse large B-cell lymphoma cells. (17916749)
2008
33
Prognostic significance of aberrant promoter hypermethylation of CpG islands in patients with diffuse large B-cell lymphomas. (18539616)
2008
34
Expression of TNF-receptor associated factor 2 correlates with poor progression-free survival time in ABC-like primary nodal diffuse large B-cell lymphomas. (18312353)
2008
35
Nuclear CD40 interacts with c-Rel and enhances proliferation in aggressive B-cell lymphoma. (17567982)
2007
36
Comparison of ataxia-telangiectasia mutated protein expression in diffuse large B-cell lymphomas of primary central nervous system and non-central nervous system origin. (17516749)
2007
37
Mutational analysis of PRDM1 indicates a tumor-suppressor role in diffuse large B-cell lymphomas. (16424392)
2006
38
Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas. (16497967)
2006
39
Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue arising in the lateral ventricle. (16194887)
2005
40
Coexistent rearrangements of c-MYC, BCL2, and BCL6 genes in a diffuse large B-cell lymphoma. (14979479)
2004
41
Primary mediastinal B-cell lymphoma: hypermutation of the BCL6 gene targets motifs different from those in diffuse large B-cell and follicular lymphomas. (15377470)
2004
42
Mutations of the BIK gene in human peripheral B-cell lymphomas. (12874789)
2003
43
Alpha-2,6-sialylation of L-PHA reactive oligosaccharides and expression of N-acetylglucosaminyltransferase V in human diffuse large B cell lymphoma. (14534692)
2003
44
Pathobiology of primary mediastinal B-cell lymphoma. (15202521)
2003
45
Plasma exchange and continuous hemodiafiltration as an initial treatment for diffuse large B-cell lymphoma-associated hemophagocytic syndrome]. (11868363)
2002
46
Role of radiation therapy in the management of primary mediastinal large B-cell lymphoma (PMLBL). (12553345)
2002
47
Somatically mutated regions of immunoglobulin on human B-cell lymphomas code for peptides that bind to autologous major histocompatibility complex class I, providing a potential target for cytotoxic T cells. (11431353)
2001
48
A reassessment of primary thyroid lymphoma: high-grade MALT-type lymphoma as a distinct subtype of diffuse large B-cell lymphoma. (10931213)
2000
49
Cerebral B-cell lymphoma following treatment for Tolosa-Hunt syndrome. (10192704)
1999
50
Splenic marginal zone lymphoma: a distinctive type of low-grade B-cell lymphoma. A clinicopathological study of 13 cases. (7573673)
1995

Variations for B-Cell Lymphomas

About this section

Expression for genes affiliated with B-Cell Lymphomas

About this section
Search GEO for disease gene expression data for B-Cell Lymphomas.

Pathways for genes affiliated with B-Cell Lymphomas

About this section

Pathways related to B-Cell Lymphomas according to GeneCards Suite gene sharing:

idSuper pathways (with members indented)ScoreTop Affiliating Genes
19.9MIR125B1, MIR29A
2
Show member pathways
Immune response T cell receptor signaling pathway59
Immune response CD28 signaling59
Immune response ICOS pathway in T helper cell59
9.7NFKB2, IGK, IGH
3
Show member pathways
Development IGF RI signaling
Immune response IL 4 signaling pathway59
Signal transduction AKT signaling59
9.7NFKB2, IGK, IGH
4
Show member pathways
Immune response BCR pathway59
Fc-epsilon receptor I signaling in mast cells36
9.5IGH, IGK, BCL6, NFKB2
59.1MIR29A, MIR223, MIR24-1, MIR15A, MIR16-1
69.1MIR125B1, MIR16-1, MIR15A, MIR223, MIR29A

Compounds for genes affiliated with B-Cell Lymphomas

About this section

GO Terms for genes affiliated with B-Cell Lymphomas

About this section

Biological processes related to B-Cell Lymphomas according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1positive regulation of B cell proliferationGO:003089010.1BCL6, TNFRSF13C
2germinal center formationGO:00024679.8NFKB2, BCL6

Sources for B-Cell Lymphomas

About this section
2CDC
12ExPASy
13FDA
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
51PubMed
52QIAGEN
57SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet